Tirzepatide: Difference between revisions
From Pharmacopedia
More actions
| [unchecked revision] | [unchecked revision] |
MDElliottMD (talk | contribs) Fix Cargo VARCHAR(300) overflow: blank structure, shorten mechanism, move chemistry/mechanism prose to PK/PD |
MDElliottMD (talk | contribs) Migrate <indication> tags to <problem> (Phase 2 of indications-to-problems rebuild) |
||
| Line 37: | Line 37: | ||
* In moderate-to-severe OSA with obesity, ~50% reduction in apnea–hypopnea index at 52 wk (SURMOUNT-OSA)<ref name="surmount-osa"/> | * In moderate-to-severe OSA with obesity, ~50% reduction in apnea–hypopnea index at 52 wk (SURMOUNT-OSA)<ref name="surmount-osa"/> | ||
| indications = < | | indications = <problem ref="diabetes-type-2" author="MDElliottMD"/> | ||
< | <problem ref="obesity" author="MDElliottMD"/> | ||
< | <problem ref="osa-obesity" author="MDElliottMD"/> | ||
| dosing = <titration slug="mounjaro-standard" author="MDElliottMD" title="Mounjaro — standard T2DM titration"> | | dosing = <titration slug="mounjaro-standard" author="MDElliottMD" title="Mounjaro — standard T2DM titration"> | ||